Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia - Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia.
Department of Anatomical Pathology, Faculty of Medicine, Universitas Indonesia - Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia.
Niger J Clin Pract. 2023 Aug;26(8):1057-1062. doi: 10.4103/njcp.njcp_222_22.
Cyclin D1 is a protein that can increase the proliferation of cancer cells. Its expression has been found in various malignancies, including gastric cancer. Cyclin D1 examinations have not been routinely performed for gastric cancer cases in Indonesia. A recent study of cyclin D1 in gastric cancer was associated with lymph node involvement, metastasis, poor prognosis, and a lack of response to platinum chemotherapy.
This study aimed to determine the relationships among cyclin D1 expression, clinicopathological features, and 2-year survival rates in gastric cancer.
This retrospective cohort study used medical records and paraffin blocks of patients suffering from gastric cancer at Cipto Mangunkusumo General Hospital, Jakarta, between 2015 and 2020. Data analysis was performed using Statistical Package for the Social Sciences (SPSS) version 20. The data were collected from 39 subjects, most of whom experienced eating disorder (69.23%), weight loss (76.92%), melena (53.85%), and anemia (51.28%). Tumor location was mostly found in the cardia and corpus of the gaster.
This study found that the proportion of overexpression of cyclin D1 was 30.77%. Cyclin D1 expression was greater in subjects with liver metastases (50% vs. 14.8%, P = 0.04). Cyclin D1 expression was not associated with tumor location, tumor, node, and metastasis (TNM) stage, or histopathological findings. Analysis of the 2-year survival rate did not find any differences between patients with cyclin D1 overexpression and those with cyclin D1 negative.
Cyclin D1 expression was associated with liver metastases in patients with gastric cancer.
细胞周期蛋白 D1 是一种能够增加癌细胞增殖的蛋白质。它的表达已在各种恶性肿瘤中被发现,包括胃癌。在印度尼西亚,胃癌病例并没有常规进行细胞周期蛋白 D1 检查。最近对胃癌中细胞周期蛋白 D1 的研究与淋巴结受累、转移、预后不良以及对铂类化疗无反应有关。
本研究旨在确定细胞周期蛋白 D1 表达与胃癌临床病理特征和 2 年生存率之间的关系。
本回顾性队列研究使用了 2015 年至 2020 年期间在雅加达 Cipto Mangunkusumo 综合医院就诊的胃癌患者的病历和石蜡块。数据分析使用社会科学统计软件包(SPSS)版本 20 进行。共纳入 39 名患者,大多数患者有饮食障碍(69.23%)、体重减轻(76.92%)、黑便(53.85%)和贫血(51.28%)。肿瘤位置主要位于贲门和胃体。
本研究发现细胞周期蛋白 D1 过表达的比例为 30.77%。有肝转移的患者中细胞周期蛋白 D1 表达更高(50% vs. 14.8%,P = 0.04)。细胞周期蛋白 D1 表达与肿瘤位置、肿瘤、淋巴结和转移(TNM)分期或组织病理学发现无关。2 年生存率分析未发现细胞周期蛋白 D1 过表达和细胞周期蛋白 D1 阴性患者之间存在差异。
胃癌患者中细胞周期蛋白 D1 表达与肝转移有关。